SureTrader Stock Hero Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

Amarantus BioScience Holdings, Inc. (AMBS)

AMBS RSS Feed
Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator 1-eye-jack, TradeSmart, joboggi, zoomboom, Rosym
Search This Board:
Last Post: 5/25/2015 4:22:51 AM - Followers: 732 - Board type: Free - Posts Today: 5



Amarantus BioScience Holdings, Inc.

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.

The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a
 diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.  (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. 
For further information, please visit www.Amarantus.com, or connect with the company in FacebookTwitter, LinkedIn & Google+

 

 

 
PRESS RELEASES & NEWS ARTICLES

Amarantus Effects Capital Restructuring in Anticipation of National Exchange Listing  -  Following the reverse split, there will be approximately 7 million common shares outstanding.
May 22, 2015
Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia - Company Completes Investigator Meetings in U.S. and E.U. in Preparation for Study Launch -  Enrollment and Dosing for 60-Patient PD-LID Study on Track to Commence 2Q 2015 
May 21, 2015
Amarantus Reports First Quarter 2015 Financial Results and Business Overview  - Eltoprazine Phase 2b clinical program on track to commence in 2Q 2015 -     
May 20, 2015   
Amarantus to Present at Two Upcoming Investor Conferences
May 19, 2015 

Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease - Demonstrated MANF Can be Precisely Delivered to Parkinson's-Associated Brain Areas.
May 15, 2015
MANF Begins its March Towards the Clinic
May 14th, 2015
Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
May 14, 2015

Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease  -  Patent Issuance Will Provide IP Protection for Lead Product Candidate Eltoprazine for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID)
May 13, 2015
Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise(R) Diagnostic for Multiple Sclerosis
May 11, 2015

Amarantus Announces the Presentation of Data Showing MANF's Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 7, 2015 
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
May 5, 2015
Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa
April 29, 2015

Developing clinical-stage products in neurology, psychiatry and orphan indications BUSINESS UPDATE CONFERENCE CALL April 9, 2015
April 9, 2015
Amarantus Reports 2014 Financial Results and Business Overview - 
 First pharmaceutical customer in the first quarter of 2015, garnered its first pharmaceutical customer in the first quarter of 2015, as the interest in trials of experimental Alzheimer's therapies is beginning to increase with high-profile successes renewing hope for the field.
April 7, 2015
A Deep Look At Amarantus’ Phase 2b Eltoprazine For Parkinson’s Dyskinesia
By Jason NapodanoWednesday, March 4, 2015
Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia - The study was partially supported by a grant from Michael J. Fox Foundation for Parkinson's Research.
Feb. 10, 2015
Congressman Fattah Meets with Biotech Company on Brain Research Efforts; Announced as Co-Chair of Alzheimer`s Caucus
February 03/15
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
Jan. 15, 2015



Predicting Alzheimer's before it starts
Published on Apr. 8, 2015
 

Developing an Accurate Test for Multiple Sclerosis
Mar. 5, 2014
 

SNNLive - Amarantus BioScience Holdings, Inc
Dec. 12, 2014
 

Amarantus BioScience
Oct. 19, 2014

 

 

 
 
    
       

 

Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva
Switzerland

info@amarantus.com
pr@amarantus.com


Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc
.

408-737-2734 x101
ir@amarantus.com


Gerald's email address

Gerald@amarantus.com







 
VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols


Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179

info@vstocktransfer.com

www.VStockTransfer.com 


 
 
 
Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline.

 
  Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information
         “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise.

   Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.
 
   Gerald E. Commissiong  -  We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above and will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.   smiley
 

                                                                            6 Conferences
•  SeeThruEquity 4th Annual Microcap Investor Conference  -  May 28, 2015    8am -  6pm,  New York City
•  Marcum MicroCap Conference Presentation - Grand Hyatt Hotel, NYC - May 28, 2015, 2:30 p.m. EDT / 11:30 a.m PDT
 LD Micro Invitational Presentation & Webcast - June 2, 2015, 1:30 p.m. EDT / 10:30 a.m. PDT, Luxe Sunset Boulevard, Los Angeles, CA
•  Bio International Convention - Philadelphia, PA - June 15-18, 2015, 
•  Alzheimer's Association International Conference  AAIC>.15   -  July 18-23, 2015, Washington, D.C. United States
•  
UN Brain Health Summoit - United Nations, NYC - July 22, 2015         

       
A webcast of the LD Micro presentation may be accessed via the News and Events page of the Investor Relations section of the Amarantus corporate web site under the IR Calendar at www.amarantus.com. A webcast replay will be available approximately two hours after the presentation ends and will be archived for 30 days.            

         smiley   Management to host conference call and webcast on Wednesday, May 27, 2015 at 5:00 p.m. EDT    yes
                         

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
AMBS News: Current Report Filing (8-k) 05/22/2015 08:31:09 AM
AMBS News: Amarantus Effects Capital Restructuring in Anticipation of National Exchange Listing 05/22/2015 07:05:00 AM
AMBS News: Current Report Filing (8-k) 05/21/2015 05:18:06 PM
AMBS News: Current Report Filing (8-k) 05/21/2015 09:17:01 AM
AMBS News: Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in P... 05/21/2015 07:05:00 AM
PostSubject
#114391  Sticky Note Buying back in a month after the R/S TradeSmart 05/22/15 02:28:41 AM
#113003  Sticky Note From the new Zack's Research Report(Apr '15) "AMBS cjstocksup 04/29/15 04:15:17 PM
#110746  Sticky Note Jason Napodano - 15 Biotech Names For 2015 Rosym 01/05/15 04:13:55 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#114618   Which indication you are referring to MANF competition. GS1 05/25/15 05:22:03 AM
#114617   right, the same thing happened with the stock joboggi 05/25/15 04:22:51 AM
#114616   I think. that stocks like this I would GS1 05/25/15 03:05:52 AM
#114615   I would wait to buy until a couple joboggi 05/25/15 02:03:29 AM
#114614   I'm still looking for an Entry here!! percival77 05/25/15 12:02:52 AM
#114613   I've owned that particular stock for several years. Goldstrike 05/24/15 11:14:51 PM
#114611   and then it traded DOWN for the better joboggi 05/24/15 10:36:27 PM
#114610   Another option would be to refinance current debt GS1 05/24/15 08:45:41 AM
#114609   Also there are preferreds Series D, E and GS1 05/24/15 07:27:46 AM
#114608   The purpose of R/S is to get rid GS1 05/24/15 06:08:31 AM
#114607   SGT Pepper is WRONG...the stock will have the a surfer 05/23/15 10:59:53 PM
#114606   I strongly believe the O/S will increase above Salexander1 05/23/15 09:07:45 PM
#114605   The 20 days is only the "D" on brharris 05/23/15 07:29:37 PM
#114604   Not true! This is were the 20 days brharris 05/23/15 07:27:35 PM
#114603   I agree, and think that is good valuation tsuguy 05/23/15 06:27:04 PM
#114602   a RS from between $0.08 and $0.10 pps JPetroInc 05/23/15 01:45:22 PM
#114601   The OS should be higher than 7 mil GS1 05/23/15 01:43:54 PM
#114600   Very True... GS1 05/23/15 01:30:48 PM
#114599   Think if AMBS had a 105M Market cap Yankeedave 05/23/15 01:29:29 PM
#114598   I think share price valuation discussion should be tsuguy 05/23/15 12:53:27 PM
#114597   Key indicators in this chart.. GS1 05/23/15 12:17:12 PM
#114595   Here is how it has fared SidVicious 05/23/15 09:59:19 AM
#114594   Re: 114593 Shadowfaxin 05/23/15 09:55:00 AM
#114592   Low float plus good news can both do SidVicious 05/23/15 09:32:32 AM
#114591   Great example here! 20% gain the day of a surfer 05/23/15 08:21:16 AM
#114590   Had overnight to think about it. Thinking that Yankeedave 05/23/15 06:20:52 AM
#114588   aha, , well if you can find just joboggi 05/23/15 01:26:26 AM
#114586   Lmao. ..no truth at all. Tuesday u can yankees18 05/22/15 11:09:07 PM
#114585   Sounds good! Rosym 05/22/15 11:07:35 PM
#114584   I know Sgt Pepper said that after today jellyfish 05/22/15 10:58:09 PM
#114583   thanks! great post! myersvodka 05/22/15 10:07:16 PM
#114582   is 150-MM Shelf Regis. in $$$ or shares JPetroInc 05/22/15 09:04:58 PM
#114581   AMBS What can you say Even if you tyfoidhana 05/22/15 08:29:01 PM
#114580   Any time! Stop by the board if you'd Titan V 05/22/15 06:27:58 PM
#114579   Get ready for the limelight. GC better be veeets 05/22/15 05:17:52 PM
#114578   * * $AMBS Video Chart 05-22-15 * * ClayTrader 05/22/15 04:46:14 PM
#114577   Agreed Gharet 05/22/15 04:33:24 PM
#114576   Jason Napodano, CFA a surfer 05/22/15 04:30:08 PM
#114575   Agreed, The TYPE of funding AMBS acquires going Yankeedave 05/22/15 04:13:35 PM
#114574   closing above 5 is GREAT!!!!! watch for continued Alapis 05/22/15 04:02:17 PM
#114573   ADXS - Advaxis was painful initially but the Robinsold 05/22/15 03:54:27 PM
#114572   revenue - is the key word JPetroInc 05/22/15 03:54:15 PM
#114571   thank you Yankeedave 05/22/15 03:45:27 PM
#114570   Totally agree Groot 05/22/15 03:41:12 PM
#114569   ONCSD 3.2B to 160M (AS) 247M to 12.35M (OS) Last week Titan V 05/22/15 03:36:25 PM
#114568   This SCAM will be $6 NOBODY buying Sgt. Pepper 05/22/15 03:36:10 PM
#114567  Restored Shares CAN'T BE TRADED for 20 DAYS Sgt. Pepper 05/22/15 03:35:53 PM
#114566   AMBS with 1.B out of 1.1B shares Yankeedave 05/22/15 03:21:28 PM
#114565   this always happens when a RS is announced. joey67 05/22/15 03:19:14 PM
#114564   I definitely don't agree. although you would have joey67 05/22/15 03:11:48 PM
PostSubject